Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing.

Genome medicine - 9 Jul 2020

Boichard Amélie, Wagner Michael J, Kurzrock Razelle

Abstract excerpt

BACKGROUND: Angiosarcoma is an aggressive tumor. Recent case series describe exceptional responses to checkpoint blockade in this disease. METHODS: Herein, we explored the genomic correlates of 48 angiosarcomas from the Angiosarcoma Project (12,499 variants analyzed in 6603 genes; whole-exome sequencing) versus 10,106 pan-cancer tumors in The Cancer Genome Atlas including 235 sarcomas but no angiosarcoma....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Disease Susceptibility

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Heterogeneity

Share to Hemangiosarcoma

Share to Immune Checkpoint Inhibitors

Share to Molecular Targeted Therapy

Share to Precision Medicine

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 32646514
DOI: 10.1186/s13073-020-00753-2
PMCID: PMC7350570

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing.PMID 32646514Read ↗

Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single centerSemantic proximity Read ↗

Immunological and Genomic Analysis Reveals Clinically Relevant Distinctions between Angiosarcoma SubgroupsSemantic proximity Read ↗

Cutaneous angiosarcoma: a current update.Semantic proximity Read ↗

The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered researchSemantic proximity Read ↗

Clinicopathological features, treatment outcomes, and prognostic factors of angiosarcoma: a 21-year experience at one centerSemantic proximity Read ↗

A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations.Semantic proximity Read ↗

Genomic analysis reveals shared genes and pathways in human and canine angiosarcomaSemantic proximity Read ↗

The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.Semantic proximity Read ↗

Mutational landscape of primary breast angiosarcoma with repeated resection and recurrence over a 15-year period: A case report.Semantic proximity Read ↗

Recurrent PTPRB and PLCG1 mutations in angiosarcoma.Semantic proximity Read ↗

Spatial transcriptomics reveal topological immune landscapes of Asian head and neck angiosarcomaSemantic proximity Read ↗

Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.